Insmed's Upcoming Presentation at J.P. Morgan Healthcare Conference: A Glimpse into the Future of Pulmonary and Inflammatory Diseases

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases, has announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET. This event will provide an opportunity for investors and industry professionals to gain insights into Insmed's pipeline progress, particularly in pulmonary and inflammatory conditions.



Insmed's most advanced programs in pulmonary and inflammatory conditions include:

1. ARIKAYCE (Amikacin Liposome Inhalation Suspension): Insmed's approved therapy for treating a chronic, debilitating lung disease. The company will likely provide updates on the ongoing ENCORE trial in patients with newly diagnosed or recurrent nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex (MAC) who had not started antibiotics. The company has completed its original target enrollment of 250 patients, and enrollment remains ongoing. Insmed received encouraging written feedback from the U.S. Food and Drug Administration (FDA) on the patient-reported outcome data produced in the Phase 3 ARISE study in December 2023. The company anticipates a topline readout for ENCORE in 2025.
2. Brensocatib: Insmed's investigational therapy for non-cystic fibrosis bronchiectasis (NCFB) and other inflammatory conditions. The company expects topline data from the Phase 3 ASPEN study in adult patients with NCFB in the latter part of the second quarter of 2024. If successful, the company anticipates a launch in the U.S. in mid-2025, followed by launches in Europe and Japan in the first half of 2026. The Data Safety Monitoring Committee for the ASPEN study held its fifth and final meeting in November 2023, with no new safety signals identified. Insmed also anticipates providing topline data from the Phase 2b BiRCh trial of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) in 2025 and initiating a Phase 2 study of brensocatib in patients with hidradenitis suppurativa (HS) in the second half of 2024.
3. Treprostinil Palmitil Inhalation Powder (TPIP): Insmed's investigational therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has completed enrollment in the Phase 2 study of TPIP in PH-ILD, exceeding its enrollment target of 32 patients with 39 patients enrolled. Topline data from the study is expected in the second quarter of 2024.

Insmed's presentation at the 43rd Annual J.P. Morgan Healthcare Conference will likely provide updates on these programs, highlighting the company's progress in developing first- and best-in-class therapies for patients with serious diseases. The company may also discuss its early-stage research programs, which encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Investors and industry professionals can expect to gain valuable insights into Insmed's pipeline progress and the company's commitment to innovation and patient care. The presentation will likely emphasize the company's dedication to transforming the lives of patients with serious and rare diseases, while also addressing the potential market opportunities and financial implications of its pipeline progress.